{
    "clinical_study": {
        "@rank": "30050", 
        "arm_group": {
            "arm_group_label": "Cognitively normal individuals"
        }, 
        "biospec_descr": {
            "textblock": "serum; white cells"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Before Alzheimer's disease (AD) clinical symptoms appear, there is a long period when\n      changes in the brain occur. In this long asymptomatic period or preclinical phase, studies\n      with populations at risk of developing AD have shown cognitive differences compared to\n      control groups without such risk. There is a need for short, sensitive, easily administered,\n      reproducible, non-expensive and independent of socio-demographic influences tests enabling\n      the detection of pre-symptomatic variations in memory, when the memory decline is still\n      within a normal range.\n\n      Study hypothesis: When evaluated with high-demanding tests of memory and executive function,\n      the cognitive performance of cognitive healthy people aged between 45 and 65, will vary\n      significantly depending on clinical, socio-demographic and genetic features"
        }, 
        "brief_title": "Study for Cognitive and Genetic Characterization of a 45-65 Years Old Population", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Individuals", 
        "detailed_description": {
            "textblock": "The purpose of Study 45-65 is to assess if:\n\n        -  Endogenous factors (clinical history, risk factors, genetic factors APOE4, etc\u2026),\n           exogenous (socio-demographic, ambient and lifestyle variables) and cognitive reserve\n           (including bilingualism) influence cognitive performance.\n\n        -  New and/or updated tests translated and validated in Spanish and Catalan when needed,\n           will provide accurate and sensitive measurements of the variability of cognitive\n           performance in this target population, representative of the preclinical phase of\n           Alzheimer's disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men and women, aged between 45 and 65 years\n\n          2. Spanish and/or Catalan speakers\n\n          3. Agreement with the study procedures and tests:\n\n               1. Clinical Interview and questionnaires associated to risk factors\n\n               2. Cognitive tests\n\n               3. Blood sample extraction for DNA analysis\n\n          4. Close relative involvement for functional evaluation of the volunteer\n\n          5. Signature of informed consent\n\n        Exclusion Criteria:\n\n          1. Cognitive impairment: MMSE <26, o MIS <6, or orientation subtest of the Barcelona\n             Test II <68, o category fluency (animals) <12\n\n          2. Functional status impairment: CDR > 0\n\n          3. Severe auditory and/or visual impairment\n\n          4. Neurodevelopmental and/or psychomotor disorder\n\n          5. Significant diseases that could currently interfere with cognition: renal failure on\n             hemodialysis, liver cirrhosis, chronic lung disease with oxygen therapy, solid organ\n             transplantation, fibromyalgia, active cancer in treatment or any other disease the\n             investigator considers could affect the participant cognition\n\n          6. Major psychiatric disorders (DSM-IV-TR) or diseases that could affect cognitive\n             abilities: major depression, bipolar disorder, schizophrenia and dementia.\n\n          7. Neurological disorders: Parkinson's disease, stroke, epilepsy and treatment with\n             frequent seizures (> 1/month) in the past year, multiple sclerosis or other serious\n             neurological disease.\n\n          8. Brain injury interfering with cognition: history of head trauma with parenchymal\n             lesion or extraaxial macroscopic large vessel ischemic stroke or hemorrhagic stroke,\n             brain surgery, brain tumors and other causes that can generate acquired brain damage\n             (cerebral chemotherapy or radiotherapy)\n\n          9. Family history of Alzheimer's disease with autosomal dominant (3 affected in two\n             different generations) and early onset age (<60 years)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "45 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Cognitive normal men and woman aged 45-65 years"
            }
        }, 
        "enrollment": {
            "#text": "2000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01835717", 
            "org_study_id": "Study 45-65/FPM 2012"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Preclinical phase of Alzheimer's disease", 
            "Asymptomatic phase of Alzheimer's disease", 
            "Cognitive normal", 
            "Exogenous factors", 
            "Endogenous factors", 
            "Episodic memory test", 
            "Executive function test", 
            "Memory binding test validation into Spanish", 
            "Memory binding test validation into Catalan"
        ], 
        "lastchanged_date": "April 18, 2013", 
        "location": {
            "contact": {
                "email": "kfauria@fpmaragall.org", 
                "last_name": "Karine Fauria, PhD", 
                "phone": "+34-933160998"
            }, 
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08003"
                }, 
                "name": "Pasqual Maragall Foundation"
            }, 
            "investigator": {
                "last_name": "Nina Gramunt, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "1", 
        "official_title": "Cross-sectional Study for Cognitive and Genetic Characterization of a 45-65 Years Old Population", 
        "overall_contact": {
            "email": "kfauria@fpmaragall.org", 
            "last_name": "Karine Fauria, PhD", 
            "phone": "+34-933160998"
        }, 
        "overall_contact_backup": {
            "email": "jdgispert@fpmaragall.org", 
            "last_name": "Juan Domingo Gispert, PhD", 
            "phone": "+34-933160983"
        }, 
        "overall_official": {
            "affiliation": "Pasqual Maragall Foundation", 
            "last_name": "Nina Gramunt, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The following tests will be administered:\nVerbal episodic memory: MBT (Memory Binding Test)\nWAIS-IV subsets: 1 Perceptual reasoning (Visual Puzzles) 2 Logical reasoning (Matrix Reasoning) 3 Executive attention and working memory (Digit span) 4 Speed of processing (Coding) 5 Abstract verbal reasoning (Similarities)\nFactors to be considered:\nHypertension, diabetes mellitus, and metabolic syndrome APOE4 Cognitive reserve (including bilingualism) Pollution, exposure to toxics, diet", 
                "measure": "Factors influencing the cognitive performance through demanding tests of episodic memory and executive function", 
                "safety_issue": "No", 
                "time_frame": "single Visit (up to 3 hours)"
            }, 
            {
                "measure": "Culturally adapted validation in Spanish and Catalan of the MBT and determination of normative data for the population under study.", 
                "safety_issue": "No", 
                "time_frame": "single visit (up to 3 hours)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01835717"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assessment of the equivalence of the in person and over the phone administration to the close relative of the Clinical Dementia Rating (CDR).", 
                "safety_issue": "No", 
                "time_frame": "single visit/telephone conversation (up to 10 min)"
            }, 
            {
                "description": "APOE genotyping will be performed", 
                "measure": "Genetic features of the population", 
                "safety_issue": "No", 
                "time_frame": "At the end of the study (13 months after study start)"
            }
        ], 
        "source": "Pasqual Maragall Foundation", 
        "sponsors": {
            "collaborator": {
                "agency": "Obra Social La Caixa, Spain", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Pasqual Maragall Foundation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "April 2013"
    }
}